FDA to consider Avastin as front-line ovarian cancer therapy

The US FDA will review an application from Basel-based Roche to extend the label for Avastin (bevacizumab) in advanced ovarian cancer.

The application covers the use of the drug, in combination with chemotherapy, in the front-line setting, followed by Avastin as monotherapy.

“About 80% of women with ovarian cancer are diagnosed in the advanced stages when the disease is difficult to treat and options are limited,” noted chief medical officer Sandra Horning.

The FDA is expected to make a decision by June 25, 2018.